Widespread
COVID-19 vaccinations not expected until mid-2021, WHO
says
Send a link to a friend
[September 04, 2020]
By Stephanie Nebehay and Emma Farge
GENEVA (Reuters) - The World Health
Organization does not expect widespread vaccinations against COVID-19
until the middle of next year, a spokeswoman said on Friday, stressing
the importance of rigorous checks on their effectiveness and safety.
|
None of the candidate vaccines in advanced clinical trials so far
has demonstrated a "clear signal" of efficacy at the level of at
least 50% sought by the WHO, spokeswoman Margaret Harris said.
Russia granted regulatory approval to a COVID-19 vaccine in August
after less than two months of human testing, prompting some Western
experts to question its safety and efficacy.
U.S. public health officials and Pfizer Inc said on Thursday a
vaccine could be ready for distribution as soon as late October.
That would be just ahead of the U.S. election on Nov. 3 in which the
pandemic is likely to be a major factor among voters deciding
whether President Donald Trump wins a second term.
"We are really not expecting to see widespread vaccination until the
middle of next year," Harris told a U.N. briefing in Geneva.
"This phase 3 must take longer because we need to see how truly
protective the vaccine is and we also need to see how safe it is,"
she added. This referred to the phase in vaccine research where
large clinical trials among people are conducted. Harris did not
refer to any specific vaccine candidate.
[to top of second column] |
All data from trials must be shared and compared, Harris said. "A lot of people
have been vaccinated and what we don't know is whether the vaccine works...at
this stage we do not have the clear signal of whether or not it has the level of
worthwhile efficacy and safety...," she added.
The WHO and GAVI vaccine alliance are leading a global vaccine allocation plan
known as COVAX that aims to help buy and distribute shots fairly. The focus is
on first vaccinating the most high-risk people in every country such as
healthcare workers.
COVAX aims to procure and deliver 2 billion doses of approved vaccines by the
end of 2021, but some countries that have secured their own supplies through
bilateral deals, including the United States, have said they will not join.
"Essentially, the door is open. We are open. What the COVAX is about is making
sure everybody on the planet will get access to the vaccines," Harris said.
(Reporting by Stephanie Nebehay and Emma Farge; Editing by Frances Kerry)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |